Homozygous Familial Hypercholesterolemia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pha

DelveInsight's "Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2022, The Food and Drug Administration (FDA) has given the drug Evkeeza® (evinacumab-dgnb) approval for the treatment of children aged 5 to 11 who have homozygous familial hypercholesterolemia (HoFH). Angiopoietin-like 3 (ANGPTL3) binds to and is inhibited by the fully human monoclonal antibody evinacumab. The approval was based on information from a three-part, open-label, single-arm study (ClinicalTrials.gov Identifier: NCT04233918), Part B of which included 14 pediatric patients with HoFH, with an average age of 9 years. Safety and effectiveness of the trial were evaluated.
• There were about 2,845 prevalent homozygous familial hypercholesterolemia cases diagnosed in the 7MM. These instances are predicted to increase by 2032 at a CAGR of 0.3% from 2019 to 2032.
• In the US, there were anticipated to be 1,349 confirmed cases of homozygous familial hypercholesterolemia. It is projected that these cases will increase over the course of the study period (2019-2032).
• It is projected that over the course of the study, this number would increase. The EU4 and the UK made up roughly 38% of all diagnosed prevalent homozygous familial hypercholesterolemia cases among the 7MM.
• Around 1,214 Homozygous Familial Hypercholesterolemia cases resulting from LDLR gene mutations were reported in 2022, followed by 67 cases of APOB, 54 cases of other mutations (LDLRAP1, APOE, SREBP2, STAP1), and 13 cases of PCSK9 gene mutation in the US.
• Key Homozygous Familial Hypercholesterolemia Companies: Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, LIB Therapeutics LLC, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, lerodalcibep, Lomitapide, and others
• The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

Homozygous Familial Hypercholesterolemia Overview
The rare and deadly inherited disease HoFH changes the metabolism of cholesterol. Low-density lipoprotein receptor (LDLR) gene mutations, as well as those in other genes involved in the metabolism of cholesterol, such as APOB or PCSK9, can cause this genetic illness.

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Report
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:
The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Homozygous Familial Hypercholesterolemia
• Prevalent Cases of Homozygous Familial Hypercholesterolemia by severity
• Gender-specific Prevalence of Homozygous Familial Hypercholesterolemia
• Diagnosed Cases of Episodic and Chronic Homozygous Familial Hypercholesterolemia
Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Homozygous Familial Hypercholesterolemia Therapies and Key Companies
• ARO-ANG3: Arrowhead Pharmaceutical
• LEQVIO (inclisiran/KJX839): Novartis/ Alnylam Pharmaceutical
• Lerodalcibep (LIB003): LIB Therapeutics
• Lomitapide: Amryt Pharma
• Inclisiran: Novartis
• Evinacumab: Ultragenyx Pharma
• ARO-ANG 3 Injection: Arrowhead Pharma
• Alirocumab: Sanofi
• CER-001: Cerenis Therapeutics, SA
• ALN-PCSSC: The Medicines Company
• lomitapide: Aegerion Pharmaceuticals, Inc.
• AK102: Akeso
• AEGR-733: Aegerion Pharmaceuticals, Inc.
• lerodalcibep: LIB Therapeutics LLC
• Lomitapide: Aegerion Pharmaceuticals, Inc.

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Market
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Market Strengths
• The clarity in disease understanding and pathogenesis have driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitor, and MTP inhibitor.
• Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

Homozygous Familial Hypercholesterolemia Market Opportunities
• Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
• Advancements in healthcare technologies and digital health solutions can potentially enhance the early detection and personalized management of HoFH

Scope of the Homozygous Familial Hypercholesterolemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Homozygous Familial Hypercholesterolemia Companies: Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, LIB Therapeutics LLC, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, lerodalcibep, Lomitapide, and others
• Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
• Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Homozygous Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Therapeutic Assessment https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Homozygous Familial Hypercholesterolemia Market Report Introduction
2. Executive Summary for Homozygous Familial Hypercholesterolemia
3. SWOT analysis of Homozygous Familial Hypercholesterolemia
4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance
5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance
6. Homozygous Familial Hypercholesterolemia Disease Background and Overview
7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia
9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices
10. Homozygous Familial Hypercholesterolemia Unmet Needs
11. Homozygous Familial Hypercholesterolemia Emerging Therapies
12. Homozygous Familial Hypercholesterolemia Market Outlook
13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2019-2032)
14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies
15. Homozygous Familial Hypercholesterolemia Market Drivers
16. Homozygous Familial Hypercholesterolemia Market Barriers
17. Homozygous Familial Hypercholesterolemia Appendix
18. Homozygous Familial Hypercholesterolemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Homozygous Familial Hypercholesterolemia Pipeline https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Homozygous Familial Hypercholesterolemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Homozygous Familial Hypercholesterolemia market. A detailed picture of the Homozygous Familial Hypercholesterolemia pipeline landscape is provided, which includes the disease overview and Homozygous Familial Hypercholesterolemia treatment guidelines.
Homozygous Familial Hypercholesterolemia Epidemiology https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Homozygous Familial Hypercholesterolemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Homozygous Familial Hypercholesterolemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Non-invasive Prenatal Testing Market https://www.delveinsight.com/report-store/non-invasive-prenatal-testing-market
Non-Invasive Prenatal Testing Market By Product Type (Instruments And Kits And Reagents), By Indication (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, And Others), By End-User (Hospitals, Diagnostic Labs, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chromosomal disorders and the increasing demand for early and non-invasive fetal diagnosis across the globe.

Orthopedic Implants Market https://www.delveinsight.com/report-store/orthopedic-implants-market
Orthopedic Implants Market By Product Type (Hip Implants, Knee Implants, Spinal Implants, Foot And Ankle Implants, And Others), By End-User (Hospitals, Orthopedic Clinics, And Others ), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of orthopedic diseases and rising demand for personalized orthopedic implants.

Analgesics Market
https://www.delveinsight.com/report-store/analgesics-market
Analgesics Market By Product Type (Opioid And Non-Opioid), By Application (Musculoskeletal, Surgical And Trauma, Cancer, And Others), By Drug Type (Prescription And Over-The-Counter (Otc)) By Distribution Channels (Hospital Pharmacy & Retail Pharmacy, And E-Commerce) by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases and rising demand of analgesics for the treatment of mild to moderate pain.

Animal Nutrition Market
https://www.delveinsight.com/report-store/animal-nutrition-market
Animal Nutrition Market By Product Type (Amino Acids, Enzymes, Vitamins And Minerals, Medicated Feed Additives, Antioxidants, And Others), By Animal Type (Poultry, Ruminant, Pet Food, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to rising awareness on animal health and nutrition and increasing industrialisation of livestock production.

Point of Care Diagnostics Market
https://www.delveinsight.com/report-store/point-of-care-diagnostics-market
Point of Care Diagnostics Market By Product Type (Instruments, Kits And Reagents), By Application (Blood Glucose Monitoring, Infectious Diseases, Cardio-Metabolic Diseases, Pregnancy & Fertility Testing, And Others), By End-User (Hospitals, Diagnostic Centers, Home Care Settings, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of infectious and other lifestyle based disorders such as diabetes and cardiovascular diseases and growing awareness on health.

Hyaluronic Acid Viscosupplementation Market
https://www.delveinsight.com/report-store/hyaluronic-acid-viscosupplementation-market
The Hyaluronic Acid Viscosupplementation Market By Treatment Type (Single Injection, Three Injections, And Five Injections), By End-User (Hospitals, Specialty Clinics, And Others), And By Geography Is Expected To Grow At A Steady CAGR forecast till 2028 owing to the increasing prevalence of osteoarthritis, particularly among the geriatric population and increasing demand for non-surgical treatment options for osteoarthritis.

Frozen Food Market
https://www.delveinsight.com/report-store/frozen-food-market
Frozen Foods Market By Product (Fruits & Vegetables, Dairy Products, Meat Products, Seafood Products, And Others), By Product Type (Raw Material, Half-Cooked And Ready-To-Eat), By Distribution Channel (Hypermarkets And Supermarkets, General Stores, E-Commerce, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to rise in the demand for ready-to-eat dishes, overall increase in the average income of individuals, rising work culture in countries, lack of time, usage of foods for extended period and others, along with the rising advancements in delivering quality and preservative-free frozen foods across the globe.

Intrauterine Pressure Catheters Market
https://www.delveinsight.com/report-store/intrauterine-pressure-catheters-market
Intrauterine Pressure Catheters Market By Product (Fluid-Filled Catheters And Transducer Tip Catheters), By End-User (Hospitals, Ambulatory Surgical Centers (ASCS), And Specialty Clinics), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing number complications in pregnancy and rising focus on maternal and fetal care across the globe.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.